Trial Profile
Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600E or NRAS Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jan 2024
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Sponsors Array BioPharma; Novartis; Pfizer
- 01 Mar 2023 Status changed from active, no longer recruiting to completed.
- 19 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 22 Nov 2022 Planned End Date changed from 8 Nov 2022 to 4 Jan 2023.